The push to detect cancer before it becomes difficult to treat is entering a new phase as researchers test whether a single blood draw could help identify multiple cancers earlier. New findings presented at the American Society of Clinical Oncology’s 2026 Annual Meeting suggest that multi-cancer early detection, or MCED, testing may help shift some cancers toward earlier stages. But the research also underscores a critical question that goes beyond whether the technology works: Who will actually have access to it?

MCED tests are designed to look for biological signals released by cancer cells into the bloodstream, including changes in DNA and other molecular markers. Instead of screening for one cancer at a time, these tests are intended to identify signals associated with multiple cancers from a single blood sample. The technology has attracted attention because many cancers do not currently have recommended screening tests for people without symptoms. The National Cancer Institute says numerous MCED tests are under development, but more research is needed to determine whether they improve outcomes for people without symptoms. No MCED test has been approved by the U.S. Food and Drug Administration. That distinction is important as interest in the tests grows. Established screening methods, including mammography for breast cancer and screening for colorectal and cervical cancers, have been evaluated over years of research and incorporated into evidence-based recommendations. The American Cancer Society continues to recommend regular screening for breast, cervical and colorectal cancers, along with risk-based approaches for lung and prostate cancer.

MCED testing is different. A blood test that detects a possible cancer signal does not by itself diagnose cancer. A positive result generally requires additional diagnostic testing to determine whether cancer is actually present, where it is located and what type of cancer it may be. A negative result also cannot guarantee that cancer is absent. The latest evidence illustrates both the promise and the uncertainty. Results from the NHS-Galleri randomized clinical trial, presented at ASCO in May 2026, included nearly 143,000 adults ages 50 to 79 who were screened annually with an MCED test in addition to standard cancer screening. The trial did not meet its primary endpoint: there was no statistically significant reduction in stage III or IV cancers among 12 prespecified cancer types. However, researchers reported a 14% reduction in stage IV cancers after three years of screening, along with a 16% increase in stage I and II cancers.

Other 2026 research has produced similarly encouraging signals. In the PATHFINDER 2 study, researchers reported that an MCED test detected 173 cancers among more than 32,000 participants with sufficient follow-up data. Among newly diagnosed primary cancers detected by the test, more than half were stage I or II. The study also found that some participants underwent invasive procedures during the diagnostic workup after receiving a positive result, illustrating why the potential benefits of earlier detection must be considered alongside the possibility of false positives, additional testing and anxiety.

Early Detection Is Only Powerful If People Can Reach It

For communities already experiencing unequal cancer outcomes, access could determine whether MCED technology reduces disparities or creates another layer of them.

The National Cancer Institute identifies disparities in cancer incidence, mortality, survival, screening rates and stage at diagnosis. People from medically underserved communities are more likely to be diagnosed with late-stage disease, while financial, physical and cultural barriers can make it harder to obtain timely health care. That means a new screening technology cannot be evaluated solely by its ability to detect a cancer signal. It also has to be considered within the health care system that surrounds the test. If a person receives a positive result but cannot afford the follow-up imaging, biopsy or specialist appointment, the benefit of detecting a possible cancer earlier can be lost.

Cost is already a consideration for commercially available MCED testing. GRAIL, the company that makes the Galleri test, lists a price of $949 and says most health insurance plans do not currently cover the test. The company also notes that diagnostic testing following a positive result is not included in that price. For patients who can afford testing out of pocket, an MCED test may be another tool to discuss with a health care provider. For patients who cannot, however, the technology could remain out of reach unless insurance coverage, public programs or other access pathways expand. That concern matters in communities already facing cancer disparities. The American Cancer Society reports that Black people have among the highest cancer death rates and lowest survival rates for many cancers in the United States. Black women, for example, are 38% more likely to die from breast cancer than White women despite having slightly lower breast cancer incidence.

Hispanic and Latino communities also face distinct cancer patterns and barriers. The American Cancer Society reports that cancer is the second-leading cause of death among Hispanic people and that Hispanic people are more likely than non-Hispanic White people to develop certain cancers, including liver, stomach and cervical cancers. The organization has also identified differences in screening, early detection and survival. For Native communities and other underserved populations, access cannot be separated from geography, transportation, availability of specialists, culturally appropriate care and trust in health systems. The NCI notes that cancer disparities are influenced by socioeconomic conditions as well as biological, environmental and health care factors. The implications extend beyond the moment when cancer is first detected. Earlier diagnosis can create more opportunities for treatment before a cancer spreads, although whether MCED testing ultimately improves survival remains an unanswered research question. That question is particularly important for metastatic breast cancer, or MBC. Stage IV breast cancer means that the disease has spread to distant parts of the body, such as the bones, liver or lungs. According to the NCI, about 5% to 6% of women with newly diagnosed breast cancer in the United States have metastatic disease when they are first diagnosed.

A 2026 study of 670 people with metastatic triple-negative breast cancer adds another layer to the discussion. Researchers found that Black patients had a higher prevalence of BRCA1/2 alterations than White patients in the study, 12% compared with 7%. The researchers did not find a statistically significant difference in overall survival between Black and White patients, but the findings highlighted differences in tumor biology and the need for larger studies examining racial differences in metastatic triple-negative breast cancer.

The connection between early detection and MBC is therefore not that an MCED test can currently prevent metastatic breast cancer. It cannot make that claim. Rather, the broader goal of stage shifting is to identify cancers before they reach advanced stages, when treatment can become more complex and options may be more limited.

For organizations focused on cancer equity, that distinction is central. The future of cancer detection will not be measured only by how many cancers a technology can find. It will also depend on whether patients have access to the test, whether positive results can be resolved quickly, whether follow-up care is affordable and whether research reflects the communities most affected by cancer disparities. The science behind MCED testing is moving quickly, and 2026 research has provided reasons for continued investigation. But the next phase cannot focus only on technological performance. If finding cancer earlier is ultimately going to change survival, early detection must reach people before disparities have already shaped their options—and the health care system must be prepared to act when that early warning arrives.